Amoun Pharmaceutical Company S.A.E.
https://www.amoun.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amoun Pharmaceutical Company S.A.E.
Bausch Hopes B+L Spin-Out Will 'Unlock' The Value Of Eye-Care Business
Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.
Bausch Investors Initially Pessimistic Following B+L Spinout
With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.
Bausch Says B+L Spinout Or IPO Could Occur During ‘October Timeframe’
During Bausch Health’s first quarter earnings call, CEO Papa said he’ll lead Bausch + Lomb following the corporate split. Overall the company reported flat revenues, but said its pandemic rebound is ongoing.
Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
Company Information
- Industry
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice